Researchers at Duke-NUS Medical School in Singapore, collaborating with scientists from Sweden's Karolinska Institutet, have pioneered a stem cell-based method to generate photoreceptor progenitor cells capable of integrating into damaged retinas and partially restoring vision in preclinical models. This advance targets cellular degeneration in the retina, a primary cause of irreversible blindness worldwide, offering hope for conditions like retinitis pigmentosa and age-related macular degeneration.

The breakthrough hinges on using specific laminin proteins—key components of the extracellular matrix—to guide human pluripotent stem cells toward becoming functional photoreceptors. In mouse models simulating human retinal diseases, these transplanted cells not only survived but formed synaptic connections with existing retinal neurons, leading to measurable improvements in visual responses via electroretinography.

The Challenge of Retinal Degeneration in Modern Societies

Retinal degeneration refers to the progressive loss of photoreceptor cells—rods and cones—in the retina, the light-sensitive layer at the back of the eye. Rods handle low-light and peripheral vision, while cones enable color and sharp central vision. When these cells die due to genetic mutations, aging, or environmental factors, patients experience tunnel vision, color blindness, and eventual total sight loss.

In Singapore, where the population is rapidly aging, age-related macular degeneration (AMD) affects about 10% of those over 50, with dry AMD—the non-neovascular form—being the most common precursor to severe vision impairment. Retinitis pigmentosa (RP), an inherited disorder, impacts roughly 1 in 4,000 Singaporeans. Sweden faces similar burdens, with AMD as the leading cause of blindness in the elderly. Globally, over 2.2 billion people live with vision impairment, and degenerative retinal diseases contribute significantly.

Traditional treatments like gene therapy or retinal implants offer limited success for advanced degeneration, as they cannot replace lost photoreceptors. Stem cell therapy emerges as a regenerative solution, aiming to repopulate the retina with new, functional cells.

Decoding the Science: Laminins and Stem Cell Differentiation

Laminins are glycoproteins forming the basement membrane in tissues, providing structural support and signaling cues for cell differentiation. The Duke-NUS team focused on laminin-521 (LN521), abundant in the human retina's interphotoreceptor matrix, which nurtures developing photoreceptors.

• Step 1: Start with human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs), ethically sourced and patient-matched for future therapies.
• Step 2: Coat culture dishes with purified recombinant human LN521 to recreate the retinal niche, avoiding animal-derived matrices for clinical safety.
• Step 3: Apply dual media mimicking embryonic retinal development: first inducing retinal progenitor identity via activin and BMP signaling, then promoting photoreceptor specification with retinoic acid and taurine.
• Step 4: Harvest photoreceptor progenitor cells (PRPCs) expressing markers like recoverin, rhodopsin, and cone opsins after 30-40 days—no manual dissection needed.

This xeno-free, chemically defined protocol, refined in a 2025 Nature Protocols publication, achieves ~17% CRX-positive (cone-rod homeobox gene) cells by day 32, cryopreservable for transplantation.

Assoc Prof Enrico Petretto's bioinformatics at Duke-NUS validated the cells' retinal identity through single-cell RNA sequencing, confirming maturity and functionality.

Groundbreaking Results from Preclinical Studies

In degenerate mouse retinas (rd1 model mimicking RP), subretinal injection of PRPCs led to 20-30% cell survival at 8 weeks post-transplant. These cells migrated to outer nuclear layer, extended axons to bipolar and horizontal cells, and dendrites to the outer plexiform layer—essential for light signal transmission.

Functional recovery was evidenced by electroretinogram (ERG) b-wave amplitudes increasing by up to 50% compared to controls, indicating restored retinal signaling. Behavioral tests showed improved light responses, a step toward vision salvage.

Key Players: The Singapore-Sweden Research Alliance

Leading the effort is Asst Prof Hwee Goon Tay from Duke-NUS's Centre for Vision Research, whose lab specializes in extracellular matrix roles in retinal repair. Prof Karl Tryggvason, a laminin pioneer, provided expertise from his Duke-NUS lab. Dr Helder Andre from Karolinska Institutet contributed retinal transplantation models.

This international team exemplifies Singapore's push for global biomedical hubs. Duke-NUS, a graduate medical school partnered with Duke University and National University of Singapore, fosters such collaborations. Explore faculty ratings and insights at Rate My Professor for Duke-NUS vision researchers.

In 2023, Duke-NUS licensed LN521/LN523 patents to Alder Therapeutics, a Swedish startup co-founded by Tryggvason, accelerating GMP-scale production for heart and eye trials.

Photo by Charles Givens on Unsplash

Recent Protocol Refinements and Scalability

Building on 2023 findings, Tay's 2025 protocol eliminates subjective steps, enabling reproducible PRPC generation suitable for good manufacturing practice (GMP). Cells post-thaw retain >90% viability, crucial for off-the-shelf therapies. This positions Singapore as a leader in regenerative ophthalmology.Alder Therapeutics updates.

Patient Impact: Hope for Singaporeans and Beyond

Singapore's National Eye Centre reports 200+ new RP/AMD cases yearly. This therapy could halt progression, preserving independence for aging baby boomers. Sweden's similar demographics amplify bilateral benefits. Globally, it addresses 36 million blind from retinal diseases.

Stakeholders like the Singapore Eye Research Institute (SERI) emphasize equitable access, with trials potentially starting in 3-5 years pending safety data.

Challenges on the Path to Clinical Trials

• Long-term integration and immune rejection mitigation.
• Scaling PRPC yield to millions per dose.
• Human retina complexity vs. mouse models.
• Regulatory hurdles for stem cell biologics.

Solutions include patient iPSC matching and immunosuppression. Duke-NUS's Phase I planning with Alder targets 2028 trials.

Duke-NUS's Role in Singapore's Vision Research Ecosystem

Duke-NUS integrates MD-PhD training, attracting top talent. The Centre for Vision Research trains postdocs in stem cell ophthalmology. Singapore's higher education landscape supports this via A*STAR and NMRC funding. Aspiring researchers can find higher ed jobs in vision sciences.

Career Opportunities in Regenerative Vision Research

Singapore's biotech boom offers roles in stem cell labs, bioinformatics, and clinical translation. Duke-NUS seeks PhD students and faculty; check university jobs and higher ed career advice for pathways. Sweden's Karolinska provides exchange programs.

Photo by Pratyush .... on Unsplash

Future Outlook: A Brighter Horizon for Sight Restoration

This breakthrough heralds a new era, potentially combining with CRISPR for genetic fixes. With Singapore-Sweden momentum, clinical milestones loom. Patients, researchers, and educators: stay engaged via Rate My Professor, explore higher ed jobs, and access career advice. Vision restoration is within reach—join the innovation at platforms like post a job.